Literature DB >> 34862490

Guselkumab effective through 2 years in PsA trial.

Sarah Onuora1.   

Abstract

Entities:  

Year:  2022        PMID： 34862490     DOI： 10.1038/s41584-021-00733-9

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.

Authors:  Iain B McInnes; Proton Rahman; Alice B Gottlieb; Elizabeth C Hsia; Alexa P Kollmeier; Xie L Xu; Yusang Jiang; Shihong Sheng; May Shawi; Soumya D Chakravarty; Désirée van der Heijde; Philip J Mease
Journal:  Arthritis Rheumatol       Date:  2022-02-07       Impact factor: 15.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.